Bill Hinshaw, CEO of Axcella Therapeutics, describes how the company’s AXA1125, with its multitargeted approach, is poised to address the devastating impact of long-COVID fatigue. More from Flagship @ JPM2023 here.
Related Companies
- Axcella Therapeutics Founded: 2011
